Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B

Abstract

This study aims to explore the efficacy of interferon-α (IFN-α) combined with either entecavir (ETV) or adefovir (ADV) therapy versus IFN-α mono-therapy for chronic hepatitis B (CHB) patients, and to identify the factors associated with treatment outcomes. Totally, 159 CHB patients receiving interferon-based treatment for 48 weeks were enrolled in this retrospective study, including IFN-α mono-therapy group (group A, n=44), IFN-α plus ADV group (group B, n=53) and IFN-α plus ETV group (group C, n=62). The primary measures of efficacy assessments were the changes in HBsAg. Cox regression analysis was used to identify the predictors of treatment outcomes. The predictive values of the factors were assessed by ROC analysis. For patients with baseline hepatitis B surface antigen (HBsAg) level <1000 IU/mL, the reductions in mean HBsAg levels at week 48 were greater in group C than that in group A (P<0.05). Higher rate of HBeAg seroconversion was achieved in the combined therapy group than in IFN-α mono-therapy group at week 48 (P<0.05). Two factors were independently associated with HBeAg seroconversion: baseline HBeAg level <2.215 log10 index/mL and ΔHBeAg (decline in HBeAg from baseline) >0.175 log10 at week 12. In conclusion, interferon-α plus ETV therapy can accelerate HBsAg decline as compared with interferon-α mono-therapy in CHB patients with lower baseline HBsAg levels, and the combination therapy was superior to IFN-α mono-therapy in increasing the rate of HBeAg seroconversion. Baseline HBeAg and ΔHBeAg at week 12 can independently predict HBeAg seroconversion in patients subject to interferon-based therapy for 48 weeks.

Keywords

chronic hepatitis B / adefovir / entecavir / combination therapy / interferon-α / ROC analysis

References

[1] Guidelines for the Prevention, CareTreatment of Persons with Chronic Hepatitis B Infection.. WHO Guidelines Approved by the Guidelines Review Committee, 2015, Geneva, World Health Organization

[2] WangFS, FanJG, ZhangZ, et al. . The global burden of liver disease: the major impact of China. Hepatology, 2014, 60(6): 2099-2108 PMID: 25164003 PMCID: 4867229

[3] LiawYF, KaoJH, PiratvisuthT, et al. . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6(3): 531-561 PMID: 26201469

[4] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012,57(1):167–185

[5] LokAS, McMahonBJ. Chronic hepatitis B: update 2009. Hepatology, 2009, 50(3): 661-662 PMID: 19714720

[6] ZoulimF, LocarniniS. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137(5): 1593-1608 PMID: 19737565

[7] ReijndersJG, PerquinMJ, ZhangN, et al. . Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology, 2010, 139(2): 491-498 PMID: 20381492

[8] van ZonneveldM, HonkoopP, HansenBE, et al. . Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004, 39(3): 804-810 PMID: 14999700

[9] BusterEH, FlinkHJ, CakalogluY, et al. . Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology, 2008, 135(2): 459-467 PMID: 18585385

[10] FungJ, LaiCL, TanakaY, et al. . The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol, 2009, 104(8): 1940-1946 PMID: 19455108

[11] SetoWK, HuiAJ, WongVW, et al. . Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut, 2015, 64(4): 667-672 PMID: 24833635

[12] MarcellinP, LauGK, BoninoF, et al. . Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351(12): 1206-1217 PMID: 15371578

[13] JanssenHL, van ZonneveldM, SenturkH, et al. . Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365(9454): 123-129

[14] PiccoloP, LenciI, DemeliaL, et al. . A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther, 2009, 14(8): 1165-1174 PMID: 20032546

[15] WursthornK, LutgehetmannM, DandriM, et al. . Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006, 44(3): 675-684 PMID: 16941693

[16] NingQ, HanM, SunY, et al. . Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014, 61(4): 777-784 PMID: 24915612

[17] BrouwerWP, XieQ, SonneveldMJ, et al. . Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology, 2015, 61(5): 1512-1522 PMID: 25348661

[18] ZoutendijkR, HansenBE, van VuurenAJ, et al. . Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis, 2011, 204(3): 415-418 PMID: 21742840

[19] ChevaliezS, HezodeC, BahramiS, et al. . Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/ nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol, 2013, 58(4): 676-683 PMID: 23219442

[20] ZhaoP, LiuW, ZhaoJ, et al. . Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B: a meta-analysis. Virol J, 2011, 8: 75 PMID: 21342505 PMCID: 3048568

[21] LeveyAS, CoreshJ, GreeneT, et al. . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med, 2006, 145(4): 247-254 PMID: 16908915

[22] HagiwaraS, KudoM, OsakiY, et al. . Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol, 2013, 85(6): 987-995 PMID: 23588724

[23] SuWW, HsuCW, LeeCM, et al. . Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol, 2014, 60: S47

[24] HEY, TangXP, ZhengXH, et al. . Therapeutic efficacy of combination therapy with interferon and a nucleoside analogue for treating chronic hepatitis B patients. J Clin Hepatol (Chinese), 2013, 29(2): 114-116

[25] LamperticoP. The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy. Hepatology, 2015, 61(5): 1459-1461 PMID: 25645624

[26] TangkijvanichP, ChittmittraprapS, PoovorawanK, et al. . A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat, 2016, 23(6): 427-438 PMID: 26387494

[27] HuangR, HaoY, ZhangJ, et al. . Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res, 2013, 43(10): 1040-1051 PMID: 23356962

[28] XieQL, ZhuY, WuLH, et al. . The efficacy and safety of entecavir and interferon combination therapy for chronic hepatitis B virus infection: A meta-analysis. PLoS One, 2015, 10(7): 132219

[29] BoniC, LaccabueD, LamperticoP, et al. . Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology, 2012, 143(4): 963-973 PMID: 22796241

[30] TanAT, HoangLT, ChinD, et al. . Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy. J Hepatol, 2014, 60(1): 54-61 PMID: 23994382

[31] LeungN, PengCY, HannHW, et al. . Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology, 2009, 49(1): 72-79 PMID: 19065670

[32] ChanHL, WongVW, ChimAM, et al. . Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther, 2010, 32(11-12): 1323-1331 PMID: 21050234

[33] TsengTC, LiuCJ, YangHC, et al. . Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 2012, 55(1): 68-76 PMID: 21858846

[34] SonneveldMJ, RijckborstV, BoucherCA, et al. . Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52(4): 1251-1257 PMID: 20830787

[35] TakkenbergRB, JansenL, de NietA, et al. . Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir. Antivir Ther, 2013, 18(7): 895-904 PMID: 23639931

[36] ThompsonAJ, NguyenT, IserD, et al. . Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 2010, 51(6): 1933-1944 PMID: 20512987

[37] XieQ, ZhouH, BaiX, et al. . A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis, 2014, 59(12): 1714-1723 PMID: 25190434

[38] MarcellinP, AhnSH, MaX, et al. . Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology, 2016, 150(1): 134-144 PMID: 26453773